Clinical trial · Interventional
Study of AQ4N in Patients With Non Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia
A Phase 1/2, Open Label, Dose Escalation Study of AQ4N for Safety, Tolerability, Pharmacokinetics and Activity in Patients With Lymphoid Neoplasms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to find answers to the following questions: * What is the largest dose of AQ4N that can be given safely one time every three weeks for 24 weeks? * What are the side effects of AQ4N when given according to this schedule? * How much AQ4N is in the blood at certain times after administration and how does the body get rid of the drug? * Will AQ4N help treat lymphoid cancer?
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | ALIAS | 0.90 |
| Small Lymphocytic Leukemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AQ4N (Chemotherapy) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall response rate
Secondary outcomes (3)
- measure
- Response duration and time to tumor progression
- measure
- Time to treatment failure
- measure
- Survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Leukemia * Tumor specimen available for evaluation (please provide 10 unstained slides) * Relapse after receiving primary treatment and at least one salvage therapy * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Laboratory test measurements * Females of childbearing potential must have a negative pregnancy test result within 3 days prior to the first dose and must agree to use an effective contraceptive method during the course of the study and for 6 months following the last dose of study drug. * Older than 18 years of age * Available for periodic blood sampling Exclusion Criteria: * Certain cardiac problems * Previous donor stem cell transplant * Known HIV, Hepatitis B, Hepatitis C infection * Previous chemotherapy, radiation or other investigational drug treatments within 4 weeks of first planned dose of study drug * Major surgery within four weeks of first planned dose of study drug * Any active viral, bacterial, or fungal infection within four weeks of first planned dose of study drug * Pregnant or breastfeeding
References
Publications (0)
Data not yet available